Vcare PharmaTech Ranked in Tier 1 of "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" for Two Consecutive Years
Published Time:
2026-06-29 17:39
Source:
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
Vcare PharmaTech has secured a spot on the Seed 100 List for six straight years since 2021. It entered Tier 1 for the first time in 2025 and retained this position this year. Its consistent listing and Tier 1 standing serve as high recognition of the company’s long-term dedication to developing innovative medicines and leading therapies, and fully validate its comprehensive strength and steady growth in technological innovation and translation, new drug research as well as clinical development.
AI Empowerment Fuels Differentiated Original Drug Design
Upholding independent incubation and original innovation, Vcare PharmaTech actively integrates cutting-edge technologies with new drug discovery, with a strategic focus on AI-enabled differentiated original molecular design. Artificial intelligence technology accelerates core R&D workflows including target identification, molecular design and candidate compound optimization, greatly boosting R&D efficiency and clinical success rates. This forward-looking strategy has built robust technological barriers across the entire innovative drug development cycle, and further consolidated the deeply collaborative industrial chain covering technology research, drug development and commercial manufacturing.
Accelerated Rollout of Innovation Pipeline; First Anti-Tumor Targeted Drug Granted Marketing Approval
Early June witnessed a landmark breakthrough in Vcare PharmaTech’s innovative drug development pipeline: VELMARTO® (Eratrectinib), the company’s self-developed Class 1 small-molecule targeted anti-tumor drug, obtained marketing approval from the NMPA. This milestone signals Vcare PharmaTech’s official transition from an R&D-focused biotech firm to an integrated enterprise covering both research and commercialization.
Meanwhile, the company’s innovation pipeline has delivered multiple key advances: one candidate drug has formally accepted NDA approval, several candidates are undergoing Phase II and Phase III clinical trials, and a batch of pre-clinical innovative drug programs are under continuous incubation. The tiered pipeline covers core therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, as well as inflammatory and autoimmune disorders, forming a globally competitive product portfolio.
Address Unmet Clinical Needs via Differentiated R&D to Forge Global Competitiveness
Moving forward, Vcare PharmaTech will stay committed to its strategic mission of "addressing unmet clinical needs through differentiated innovation". The company will further expand its innovative drug pipeline, leverage the technical strengths of AI-powered original discovery, and speed up the research, translational development and commercial launch of more Class 1 innovative medicines. It aims to build a diversified innovative drug portfolio with solid technological barriers and outstanding clinical competitiveness across multiple disease areas, deliver superior treatment options for patients worldwide, and fuel high-quality growth of China’s pharmaceutical innovation sector.
About the Seed 100 List
The Seed 100 List selects enterprises representing the innovation potential of China’s pharmaceutical industry. Compiled by authoritative industrial media E Pharma Manager, the ranking adopts an evaluation framework centered on innovation foundation, innovation process and innovation output. Based on Clarivate’s Cortellis competitive intelligence, clinical trial data and Derwent Innovation patent database, evaluators analyze metrics including the number of granted patents, total patent citations, ongoing clinical trial programs, and approved/marketed new medicines to shortlist the top 100 innovative pharmaceutical enterprises.
Previous Page
Related News
27
2022
/
12
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.
View Details
19
2022
/
05
Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.
View Details
06
2022
/
05
Jiangsu Vcare Closes Series A2 Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
View Details
22
2021
/
11
On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.
View Details
18
2021
/
08
Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules
On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.
View Details
16
2021
/
08
Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn